ELVN - NASDAQ
Enliven Therapeutics, Inc.
$37.48
+4.0%Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
At a Glance
Live Snapshotelvn
Research Development Expenses
Last Annual Value
85.86M
3-Year CAGR
40%
5-Year CAGR
60%
10-Year CAGR
27%
Enliven Therapeutics, Inc. Competitors Analysis of research-development-expenses
| Company | research-development-expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Enliven Therapeutics, Inc. NASDAQ:ELVN | 85.86M | 10.0% | 33.2% | N/A | |
 Dianthus Therapeutics, Inc. NASDAQ:DNTH | 145.64M | 64.3% | 63.1% | 38.1% | |
 ORIC Pharmaceuticals, Inc. NASDAQ:ORIC | 109.82M | 8.8% | 14.1% | N/A | |
 Atai Beckley Inc. NASDAQ:ATAI | 53.06M | -5.0% | 2.1% | N/A | |
 Relay Therapeutics, Inc. NASDAQ:RLAY | 261.38M | -7.5% | 8.6% | N/A | |
 Inhibrx Biosciences, Inc. NASDAQ:INBX | 113.03M | -16.0% | 9.6% | 20.9% | |
 Sana Biotechnology, Inc. NASDAQ:SANA | 131.98M | -15.6% | -15.5% | N/A | |
 Nektar Therapeutics NASDAQ:NKTR | 117.33M | 0.9% | -21.8% | -5.4% | |
 Precigen, Inc. NASDAQ:PGEN | 41.33M | -5.3% | -2.9% | -9.5% | |
 Syndax Pharmaceuticals, Inc. NASDAQ:SNDX | 258.78M | 16.7% | 24.0% | 23.4% |
Enliven Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your ELVN research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.